<DOC>
	<DOCNO>NCT01970098</DOCNO>
	<brief_summary>The purpose study investigate superiority KPS-0373 placebo , evaluate safety pharmacokinetics KPS-0373 SCD patient .</brief_summary>
	<brief_title>A Confirmatory Study KPS-0373 Patients With Spinocerebellar Degeneration ( SCD )</brief_title>
	<detailed_description />
	<mesh_term>Spinocerebellar Degenerations</mesh_term>
	<mesh_term>Spinocerebellar Ataxias</mesh_term>
	<mesh_term>Thyrotropin-Releasing Hormone</mesh_term>
	<criteria>Japanese SCD patient mild moderate ataxia Patients secondary ataxia Patients clinically significant hepatic , renal , cardiovascular dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Spinocerebellar degeneration ( SCD )</keyword>
	<keyword>Thyrotropin-Releasing Hormone ( TRH )</keyword>
	<keyword>Spinocerebellar Ataxia ( SCA )</keyword>
	<keyword>Cortical Cerebellar Atrophy ( CCA )</keyword>
</DOC>